目的 观察吉西他滨联合顺铂(GP)方案治疗蒽环类耐药晚期乳腺癌的疗效与不良反应.方法 回顾性分析2007年1月至2009年1月我院采用GP方案治疗32例蒽环类耐药的晚期乳腺癌患者的临床资料.结果 完全缓解(CR)2例(6.25％),部分缓解(PR) 15例(46.88％),稳定(SD) 12例(37.5％),进展(PD)3例(9.37％),总有效率为53.1％；全组中位疾病进展时间(TTP) 6.2个月,中位生存时间(MST) 12.6个月,1年生存率为58.7％,3年生存率为23.6％；主要不良反应为血液系统及消化道反应.结论 吉西他滨联合顺铂方案治疗蒽环类耐药晚期乳腺癌有较好的疗效,患者对其不良反应可以耐受.%Objective To evaluate the efficacy and toxicity of gemcitabine-cisplatin regimen in treating anthracycine-resistant advanced breast cancer. Methods Data of 32 patients with anthracycine-resistant advanced breast cancer treated with gemcitabine-cisplatin regimen from Jan. 2007 to Jan. 2009 were retrospectively analyzed. Results Two cases (6.25%) had complete response (CR), 15 cases(46.88%) had partial response (PR), while 12 cases (37.5%) had stable disease (SD) and 3 cases (9.37%) had progressive disease (PD). The overall response rate was 53.1%, with a median time to progression of 6.2 months. The median survival times were 12.6 months. The 1-year and 3-year overall survival rates were 58.7% and 23.6%, respectively. The most frequent side effects were hematolog-ic and gastrointestinal toxicity. Conclusion Gemcitabine combined with cisplatin was an effective regimen for patients with anthracycine-resistant advanced breast cancer, with the acceptable toxicity profile.
展开▼
